Rotavirus vaccine - GlaxoSmithKline

Drug Profile

Rotavirus vaccine - GlaxoSmithKline

Alternative Names: 444563; 89-12; GSK 444563; GSK Biologicals' liquid human rotavirus vaccine 444563; GSK rotavirus vaccine 444563; GSK vaccine 444563; HRV PCV-free liquid vaccine; Human Rotavirus Vaccine 444563; Live-attenuated human G1P[8] rotavirus vaccine - Japan Vaccine; RIX-4414; Rotarix; Rotavirus vaccine - AVANT Immunotherapeutics/Japan Vaccine; Rotavirus vaccine 444563 - Japan Vaccine

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AVANT Immunotherapeutics; Cincinnati Childrens Hospital Medical Center
  • Developer GlaxoSmithKline; Japan Vaccine
  • Class Attenuated vaccines; Rotavirus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Rotavirus infections

Most Recent Events

  • 07 Jul 2017 GlaxoSmithKline plans a phase III trial for Rotavirus infection(In volunteers, In infants, Prevention) (NCT03207750)
  • 01 Oct 2016 GlaxoSmithKline initiates enrolment in a phase III trial for Rotavirus infections (In infants, Prevention) in USa, Germany and Finland (NCT02914184)
  • 22 Sep 2016 GlaxoSmithKline plans a phase IIIa trial for Rotavirus infections (In infants, Prevention) in Costa Rica, Finland, Japan, South Korea and USA (PO) (NCT02914184)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top